Tag: FDA AMT
-
NanoMosaic Earns FDA AMT Designation for Advanced Gene Therapy Analytics
NanoMosaic Secures FDA AMT Designation for Advanced Gene Therapy Analytics NanoMosaic has been awarded the FDA’s Advanced Manufacturing Technology (AMT) designation, a status reserved for platforms that demonstrably improve efficiency, product quality, and regulatory readiness in complex manufacturing environments. This recognition underscores NanoMosaic’s commitment to advancing gene therapy analytics and supporting developers navigating the regulatory…
-
NanoMosaic Secures FDA AMT Designation to Accelerate Advanced Gene Therapy Analytics
NanoMosaic Secures FDA AMT Designation to Accelerate Advanced Gene Therapy Analytics NanoMosaic has earned the U.S. Food and Drug Administration’s (FDA) Advanced Manufacturing Technology (AMT) designation, signaling a pivotal step for developers and manufacturers leveraging the company’s analytics platform for gene therapies. The designation aims to streamline regulatory engagement, improve product quality, and expedite the…
-
NanoMosaic Earns FDA Advanced Manufacturing Technology Designation to Accelerate Gene Therapy Analytics
Overview: A Milestone for Gene Therapy Analytics NanoMosaic has secured the U.S. Food and Drug Administration’s (FDA) Advanced Manufacturing Technology (AMT) designation for its cutting-edge analytics platform. This recognition underscores the company’s ability to streamline complex gene therapy workflows, enhance product quality, and improve FDA engagement for developers and manufacturers pursuing advanced therapies. As gene…